Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications

New therapies are urgently needed in melanoma particularly in late-stage patients not responsive to immunotherapies and kinase inhibitors.

Source: Journal of Experimental and Clinical Cancer Research - February 21, 2020 Category: Cancer & Oncology Authors: Wei Liu, Pawe ł Stachura, Haifeng C. Xu, Nikkitha Umesh Ganesh, Fiona Cox, Ruifeng Wang, Karl S. Lang, Jay Gopalakrishnan, Dieter Häussinger, Bernhard Homey, Philipp A. Lang and Aleksandra A. Pandyra Tags: Research Source Type: research